Steven McCune

6.8k total citations · 1 hit paper
19 papers, 1.6k citations indexed

About

Steven McCune is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Steven McCune has authored 19 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Genetics. Recurrent topics in Steven McCune's work include Cancer Immunotherapy and Biomarkers (6 papers), Advanced Breast Cancer Therapies (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Steven McCune is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Advanced Breast Cancer Therapies (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Steven McCune collaborates with scholars based in United States, Canada and Germany. Steven McCune's co-authors include Tim M. Townes, Alessandro Morabito, Niels Reinmuth, Alan Sandler, Ahad A. Sadiq, Hans‐Georg Kopp, Lijia Wang, Venice Archer, Tarek Mekhail and Marcin Kowanetz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Nucleic Acids Research.

In The Last Decade

Steven McCune

19 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

2019 1.1k citations Howard West, Michael McCleod et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven McCune United States	10	1.1k	815	330	240	153	19	1.6k
Sajida Piperdi United States	17	521 0.5×	464 0.6×	410 1.2×	252 1.1×	88 0.6×	25	1.1k
Jena D. French United States	16	668 0.6×	292 0.4×	294 0.9×	650 2.7×	175 1.1×	27	1.7k
Laura Ridolfi Italy	20	1.2k 1.0×	309 0.4×	463 1.4×	877 3.7×	49 0.3×	67	1.6k
Renata Duchnowska Poland	18	719 0.6×	530 0.7×	309 0.9×	59 0.2×	52 0.3×	68	1.1k
Delicia Carey United States	15	596 0.5×	242 0.3×	491 1.5×	139 0.6×	357 2.3×	21	1.2k
Ahad A. Sadiq United States	9	1.3k 1.1×	1.0k 1.3×	204 0.6×	223 0.9×	36 0.2×	17	1.6k
Christina Matheny United States	14	516 0.5×	258 0.3×	615 1.9×	161 0.7×	53 0.3×	29	1.2k
Adam Cooper Australia	16	669 0.6×	257 0.3×	318 1.0×	292 1.2×	40 0.3×	38	1.1k
Diana Miao United States	12	952 0.8×	328 0.4×	769 2.3×	715 3.0×	74 0.5×	23	1.7k
Amandine Alard United States	10	851 0.7×	315 0.4×	576 1.7×	724 3.0×	37 0.2×	13	1.6k

Countries citing papers authored by Steven McCune

Since Specialization

Citations

This map shows the geographic impact of Steven McCune's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven McCune with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven McCune more than expected).

Fields of papers citing papers by Steven McCune

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven McCune. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven McCune. The network helps show where Steven McCune may publish in the future.

Co-authorship network of co-authors of Steven McCune

This figure shows the co-authorship network connecting the top 25 collaborators of Steven McCune. A scholar is included among the top collaborators of Steven McCune based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven McCune. Steven McCune is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Tripathy, Debu, Joanne L. Blum, Meghan Karuturi, et al.. (2024). Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer: final results from the POLARIS trial. The Oncologist. 30(7). 2 indexed citations

Karuturi, Meghan, Joseph C. Cappelleri, Joanne L. Blum, et al.. (2023). Measures of functional status in older patients treated with palbociclib for advanced breast cancer. Journal of Geriatric Oncology. 15(1). 101670–101670. 2 indexed citations

Sharma, Padmanee, Michael Krainer, Fred Saad, et al.. (2023). Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.. Journal of Clinical Oncology. 41(6_suppl). 22–22. 17 indexed citations

Dowlati, Afshin, Sandrine Hiret, Achim Rittmeyer, et al.. (2022). An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS8600–TPS8600. 1 indexed citations

Tripathy, Debu, Zhe Zhang, Joanne L. Blum, et al.. (2022). Abstract P1-18-05: Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS. Cancer Research. 82(4_Supplement). P1–18. 1 indexed citations

Karuturi, Meghan, Gabrielle B. Rocque, Joseph C. Cappelleri, et al.. (2022). Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS. Cancer Research. 82(4_Supplement). P1–18. 2 indexed citations

Long, Georgina V., Caroline Robert, Marcus O. Butler, et al.. (2021). Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. Clinical Cancer Research. 27(19). 5280–5288. 24 indexed citations

Pachynski, Russell K., Margitta Retz, Jeffrey C. Goh, et al.. (2021). CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(15_suppl). 5044–5044. 10 indexed citations

Lindeman, Geoffrey J., Rebecca Bowen, Katarzyna J. Jerzak, et al.. (2021). Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).. Journal of Clinical Oncology. 39(15_suppl). 1004–1004. 23 indexed citations

10.

West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(7). 924–937. 1137 indexed citations breakdown →

11.

Long, Georgina V., Caroline Robert, Marcus O. Butler, et al.. (2019). Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.. Journal of Clinical Oncology. 37(15_suppl). 9514–9514. 3 indexed citations

12.

West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC. Cancer Research. 79(13_Supplement). CT200–CT200. 2 indexed citations

13.

Richards, Donald, Maen Hussein, Steven McCune, et al.. (2018). What is the benefit from second- and third-line (2L and 3L) therapy for extensive disease small cell lung cancer (ED-SCLC)? A prospective study of patterns, discontinuation, and survival in US community practices.. Journal of Clinical Oncology. 36(15_suppl). e20567–e20567. 1 indexed citations

14.

Levasseur, Dana N., Thomas M. Ryan, Michael P. Reilly, et al.. (2004). A Recombinant Human Hemoglobin with Anti-sickling Properties Greater than Fetal Hemoglobin. Journal of Biological Chemistry. 279(26). 27518–27524. 54 indexed citations

15.

McCune, Steven, Joseph O. Moore, Carlos M. DeCastro, et al.. (2002). Alemtuzumab in Relapsed or Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia. Leukemia & lymphoma. 43(5). 1007–1011. 31 indexed citations

16.

McCune, Steven. (2001). Monoclonal Antibody Therapy in the Treatment of Non-Hodgkin Lymphoma. JAMA. 286(10). 1149–1149. 9 indexed citations

17.

Chen, Wenyong, Evans C. Bailey, Steven McCune, Jian-Yun Dong, & Tim M. Townes. (1997). Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proceedings of the National Academy of Sciences. 94(11). 5798–5803. 218 indexed citations

18.

Reilly, Michael P., Steven McCune, Thomas M. Ryan, et al.. (1994). [26] Preparation of recombinant hemoglobin in transgenic mice. Methods in enzymology on CD-ROM/Methods in enzymology. 231. 403–434. 9 indexed citations

19.

McCune, Steven & Tim M. Townes. (1994). Retroviral vector sequences inhibit human β-globin gene expression in transgenic mice. Nucleic Acids Research. 22(21). 4477–4481. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact